Cardiol Therapeutics is advancing its proprietary pharmaceutical cannabidiol therapeutics program to treat life-threatening heart disease
Verona Pharma looks forward to phase III ensifentrine trials after US$200mln fundraise
Antibe Therapeutics is ready for a big push as it progresses pain management drug through clinical trials
Only registered members can use this feature.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.